On September 12, 2023, Genevoyager (Wuhan) Co., Ltd. (“Genevoyager”) proudly announces the successful completion of its Series A financing round, securing substantial funding to accelerate the expansion of its Gene Therapy Contract Development and Manufacturing Organization (CDMO) services. The financing, exceeding 100 million yuan, was led by SDIC Venture Capital and Homsun Capital, marking a significant milestone in Genevoyager's strategic growth.

The capital injection is strategically designated to expedite the construction of current Good Manufacturing Practice (cGMP) facilities, bolster system development in research, patents, talent acquisition, and facilitate business promotion. Genevoyager is committed to solidifying its global presence as a competitive gene therapy CDMO platform, offering comprehensive services to collaborative partners.

This successful Series A financing follows Genevoyager's pre-Series A funding in 2022, where notable investments were received from Ningbo Runke Venture Capital, Yunion Healthcare Ventures, and Star Capital.

Genevoyager specializes in large-scale viral vector preparation and delivery technology development, positioning itself as a prominent one-stop CRO/CDMO service provider for gene therapy. The company has established a vector research and development platform covering adeno-associated viruses, lentiviruses, adenoviruses, oncolytic viruses, etc. With proprietary technologies, including the patented One-Bac 4.0 system, Genevoyager is recognized for its efficiency in large-scale production of AAV- and protein-based products.

The company boasts a highly skilled team of 300 professionals, covering expertise in viral vector research and development, preclinical efficacy evaluation, CMC process development, QA/QC, and GMP production. Genevoyager's cGMP facility in Jiangxia District, Wuhan spans 68,000ft2 and encompasses 5 viral vector production lines and 1 fill & finish line, set to commence operations in mid-October 2023.

Genevoyager GMP facilities

Statements from Genevoyager Leadership and Investors

Dr. Xiaobin He, CEO of Genevoyager:

"This Series A financing marks a pivotal moment for Genevoyager, empowering our transition into a leading gene therapy CDMO platform. We are unwavering in our commitment to continuous innovation, platform establishment, and service expansion, with the goal of enhancing global accessibility to gene therapy products."

SDIC Venture Capital:

"Genevoyager's expertise in gene therapy positions it as a key player in the evolving landscape. This investment aims to contribute to the global advancements in gene therapy products and strengthen Genevoyager's pivotal role in this industry."

Homsun Capital:

"Genevoyager's independently developed technologies, including the One-Bac 4.0 system, provide significant advantages. This financing will support the broader applications of Genevoyager's technology, contributing to the swift resolution of unmet medical needs in gene therapy."

About Genevoyager

Genevoyager is a leading provider of one-stop CRO/CDMO services for gene therapy products. With a proprietary technology platform for large-scale AAV production and cGMP facilities, Genevoyager is dedicated to advancing healthcare by supporting its partners to develop safe, effective, affordable, and accessible AAV gene therapy products to address unmet medical needs.

Genevoyager possesses a proprietary insect baculovirus system known as One-Bac 4.0. This system employs a novel approach for regulating AAV (Adeno-Associated Virus) expression cassettes, coupled with critical process optimizations. It attains higher yield, better infectivity, and higher full-capsid ratio for large-scale manufacturing. The single-batch production capacity of the One-Bac 4.0 system can reach up to 1E+18 vg.

Its subsidiary, BrainVTA (Wuhan) Co., Ltd., (BrainVTA), is a Contract Research Organization (CRO) company that has been delivering innovative viral reagents and customized technical services since 2014. BrainVTA has established itself as a leader in the academic market, dedicated to enhancing the human condition through advancements in biotechnology.

About SDIC Venture Capital

Established in 2016, SDIC Venture Capital is a specialized entrepreneurial investment fund management company. It focuses on transforming scientific and technological achievements in key areas such as advanced manufacturing, electronic information, biopharmaceuticals, materials, and energy.

About Homsun Capital

Shanghai Homsun Equity Investment Fund Management Co., Ltd. is engaged in private equity investment fund management, with a focus on equity investment in small and medium-sized enterprises with rapid growth opportunities.